Department of Neurology and Cerebrovascular Medicine, Saitama Medical University International Medical Center, Saitama, Japan.
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e168-72. doi: 10.1016/j.jstrokecerebrovasdis.2012.10.012. Epub 2012 Dec 14.
The objective of this study was to evaluate treatment outcomes of tissue plasminogen activator (t-PA) infusion for hyperacute branch atheromatous disease (BAD) within 3 hours after onset.
A total of 152 BAD patients with lenticulostriate artery (LSA) or paramedian pontine artery (PPA) territory infarcts (LSA 114; PPA 38) were hospitalized between April 2007 and June 2012. Of these, 21 BAD patients (LSA 19; PPA 2) arrived at the hospital within 3 hours after onset, and, among these, 8 patients who received t-PA infusion (.6 mg/kg) were included in this study. All BAD patients who received t-PA infusion had LSA territory infarcts.
Six of 8 patients (75%) had improvement of neurologic findings within 60 minutes after t-PA infusion, but neurologic findings deteriorated within 24 hours in 4 of these patients (67%). In all patients with deterioration, diffusion-weighted imaging after 24 hours revealed infarct expansion. One patient (13%) had symptomatic intracranial hemorrhage. After 3 months, the modified Rankin Scale (mRS) score was 0 to 2 in 6 patients (75%) and 3 to 6 in 2 patients (25%).
With t-PA infusion for BAD, symptoms transiently improved, but the rate of symptom deterioration was high. The outcome after 3 months was relatively good.
本研究旨在评估发病后 3 小时内组织型纤溶酶原激活物(t-PA)输注治疗超急性期分支粥样硬化性疾病(BAD)的疗效。
2007 年 4 月至 2012 年 6 月期间,共收治 152 例纹状体动脉(LSA)或旁正中脑桥动脉(PPA)梗死的 BAD 患者(LSA 114 例,PPA 38 例)。其中,21 例 BAD 患者(LSA 19 例,PPA 2 例)在发病后 3 小时内入院,其中 8 例接受 t-PA 输注(0.6mg/kg),纳入本研究。所有接受 t-PA 输注的 BAD 患者均有 LSA 区域梗死。
8 例患者中,6 例(75%)在 t-PA 输注后 60 分钟内神经功能改善,但其中 4 例(67%)在 24 小时内神经功能恶化。所有恶化的患者在 24 小时后弥散加权成像均显示梗死扩大。1 例患者(13%)出现症状性颅内出血。3 个月后,6 例患者(75%)改良 Rankin 量表(mRS)评分为 0-2 分,2 例患者(25%)为 3-6 分。
对于 BAD,t-PA 输注后症状暂时改善,但症状恶化率较高。3 个月后的预后相对较好。